Fredag 27 December | 12:55:48 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-05-09 N/A Årsstämma
2025-02-13 08:00 Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-06-03 - Split IMMU 20:1
2024-05-20 - X-dag ordinarie utdelning IMMU 0.00 SEK
2024-05-17 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-12-13 - Extra Bolagsstämma 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-15 - X-dag ordinarie utdelning IMMU 0.00 SEK
2023-05-12 - Årsstämma
2023-05-12 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-18 - Extra Bolagsstämma 2022
2022-11-11 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-11 - X-dag ordinarie utdelning IMMU 0.00 SEK
2022-05-10 - Årsstämma
2022-05-10 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-05 - X-dag ordinarie utdelning IMMU 0.00 SEK
2021-05-04 - Årsstämma
2021-05-04 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2021-01-22 - Extra Bolagsstämma 2021
2020-12-18 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2
2020-04-29 - X-dag ordinarie utdelning IMMU 0.00 SEK
2020-04-28 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-18 - Bokslutskommuniké 2019
2019-11-06 - Kvartalsrapport 2019-Q3
2019-08-20 - Kvartalsrapport 2019-Q2
2019-04-26 - X-dag ordinarie utdelning IMMU 0.00 SEK
2019-04-25 - Årsstämma
2019-04-25 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018
2018-11-07 - Kvartalsrapport 2018-Q3
2018-08-17 - Kvartalsrapport 2018-Q2
2018-05-04 - Kvartalsrapport 2018-Q1
2018-04-26 - X-dag ordinarie utdelning IMMU 0.00 SEK
2018-04-25 - Årsstämma
2018-02-16 - Bokslutskommuniké 2017
2017-12-04 - Extra Bolagsstämma 2017
2017-11-17 - Kvartalsrapport 2017-Q3
2017-08-18 - Kvartalsrapport 2017-Q2
2017-05-19 - Kvartalsrapport 2017-Q1
2017-04-27 - X-dag ordinarie utdelning IMMU 0.00 SEK
2017-04-26 - Årsstämma
2017-02-17 - Bokslutskommuniké 2016
2016-05-20 - Kvartalsrapport 2016-Q3
2016-02-19 - Kvartalsrapport 2016-Q2
2015-12-03 - Årsstämma
2015-09-18 - Bokslutskommuniké 2015
2015-05-21 - Kvartalsrapport 2015-Q3
2015-02-20 - Kvartalsrapport 2015-Q2
2014-12-04 - X-dag ordinarie utdelning IMMU 0.00 SEK
2014-12-03 - Årsstämma
2014-11-18 - Kvartalsrapport 2015-Q1
2014-09-17 - Bokslutskommuniké 2014
2014-05-07 - Kvartalsrapport 2014-Q3
2014-02-18 - Kvartalsrapport 2014-Q2
2013-12-04 - X-dag ordinarie utdelning IMMU 0.00 SEK
2013-12-03 - Årsstämma
2013-12-03 - Kvartalsrapport 2014-Q1
2013-09-10 - Bokslutskommuniké 2013

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Mendus är verksamt inom medicinteknik. Bolaget producerar terapeutiska vacciner som används inom området för onkologi. Bolaget driver huvudsakligen utveckling inom immunterapi med fokus på behandling av allvarliga tumörer. Exempel på sjukdomar som produkterna används mot innefattar njur- och levercancer. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget gick tidigare under namnet Immunicum och har idag sitt huvudkontor i Stockholm.
2024-10-08 08:00:00

Press Release

Stockholm, Sweden, October 8, 2024
 

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will participate in the following upcoming industry and investor conferences in the period October-November 2024:

LSX Nordic conference
Copenhagen, Denmark, October 8-9

Mendus CEO Erik Manting will hold a company Showcase presentation on October 9, 11.00 CET. Dr Manting will also participate in a panel discussion titled “ATMPs and a New Paradigm Shift for Patients: Initiatives and Ambitions in the Nordics” on October 9, 14.50 CET. The panel focuses on how new advanced therapies (ATMPs) offer life-changing potential for many patients who battle with serious rare diseases and cancers. Mendus has entered into an ATMP manufacturing alliance with NorthX Biologics, to enable large-scale manufacturing of its lead product, vididencel.

Biotech, Healthtech & Medtech Investment | LSX Nordic Congress (informaconnect.com)

CONDOR Symposium
Bordeaux, France, October 10-11

Mendus CMO Jeroen Rovers will participate in the annual symposium of the Precision Medicine and Immunotherapy of Sarcoma (CONDOR) program, held at Institut Bergonié, Bordeaux, France. Together with Institut Bergonié, Mendus is preparing to study the intratumoral primer ilixadencel in combination with regorafenib and avelumab as a novel treatment for soft tissue sarcoma as part of the REGOMUNE trial. See our July 23 press release of for more background Mendus announces collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas - Mendus. For more information on the CONDOR program, please visit HOME - CONDOR PROGRAM - Therapeutic Management of STS

EVENTS & MEETINGS - CONDOR PROGRAM - Management of STS

BioEurope
Stockholm, Sweden, November 4-6

Mendus CEO Erik Manting will participate for investor and industry meetings.

BIO-Europe | Meet dealmakers from biotech, pharma and finance (informaconnect.com)

SITC 2024
Houston, Texas, USA, November 6-10

On November 8, Mendus will present preclinical data supporting the combination of its intratumoral primer ilixadencel with the immune checkpoint inhibitor avelumab at the 39th annual meeting of the Society for Immunotherapy of Cancer (SITC). SITC abstract titles are available via Titles and Publications - SITC 2024 (sitcancer.org), abstract number is 761. Together with Institut Bergonié, Mendus is preparing study ilixadencel in combination with avelumab and the tyrosine kinase inhibitor regorafenib in soft tissue sarcoma, as part of the REGOMUNE trial.

Home - SITC 2024 (sitcancer.org)

ALLG Scientific Meeting
Melbourne, Australia, November 12-15

Mendus CMO Jeroen Rovers will participate in the biannual investigator meeting organized by the Australasian Leukaemia and Lymphoma Group (ALLG). Together with ALLG, Mendus will study its lead program vididencel as a novel maintenance therapy for acute myeloid leukemia (AML) in combination with oral azacitidine (aza) in the AMLM22-CADENCE trial. Mendus and ALLG are in the process of opening up to 9 clinical centres in 2024Q4 to support the first stage of the trial, which comprises 40 patients to study the safety of the vididencel + oral aza combination. This stage will be followed by another 100 patients to study efficacy of the combination versus oral aza, currently the only approved AML maintenance drug.

November 2024 Scientific Meeting | The Australasian Leukaemia and Lymphoma Group (allg.org.au)

Jefferies Healthcare Conference
London, UK, November 19-21

Mendus CEO Erik Manting will participate for investor and industry meetings.

Jefferies Global Healthcare Conference 2024 | Jefferies.com